Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension (TM) Delivery Technology in patients with chronic obstructive pulmonary disease

摘要

Background: The long-term safety and efficacy of a novel Co-Suspension (TM) Delivery Technology glycopyrrolate (GP)/formoterol fumarate (FF) 18/9.6 mu g fixed-dose combination metered dose inhaler (GFF MDI) were investigated in a 28-week safety extension study (PINNACLE-3, NCT01970878) of two ran-domized controlled Phase III trials (PINNACLE-1 and -2; NCT01854645 and NCT01854658) in subjects with moderate-to-very severe chronic obstructive pulmonary disease (COPD).